Waldenstrom Macroglobulinemia Market

Market Overview:

The 7 major Waldenstrom macroglobulinemia markets reached a value of US$ 152.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 234.2 Million by 2034, exhibiting a growth rate (CAGR) of 4% during 2024-2034.

The Waldenstrom macroglobulinemia market has been comprehensively analyzed in IMARC's new report titled "Waldenstrom Macroglobulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Waldenstrom macroglobulinemia refers to a rare form of cancer that belongs to a group of disorders known as lymphoproliferative neoplasms. It is characterized by the overproduction of a specific type of abnormal white blood cell called lymphoplasmacytic cells, which accumulate in the bone marrow and produce monoclonal immunoglobulin M (IgM) protein. The most common symptoms associated with the illness include fatigue, weakness, enlarged lymph nodes and spleen, anemia, bleeding problems, easy bruising, nosebleeds, etc. Individuals suffering from this ailment may also experience indications related to high levels of IgM, such as thickened blood or hyperviscosity. The diagnosis of Waldenstrom macroglobulinemia involves several steps, including medical history evaluation, physical examination, laboratory tests, and imaging studies. A bone marrow biopsy is also crucial to detect characteristic findings and confirm the presence of abnormal lymphocytes in patients. The healthcare provider may further perform numerous other diagnostic procedures and tests, like a complete blood count, a computed tomography scan, serum protein electrophoresis, etc., to validate the underlying cause as well as evaluate the extent and spread of the disease.

The increasing cases of inherited disorders resulting from genetic mutations, which cause uncontrolled growth and accumulation of lymphoplasmacytic cells, are primarily driving the Waldenstrom macroglobulinemia market. In addition to this, the growing geriatric population, who are susceptible to various physiological changes and impaired immune system functioning, is creating a positive outlook for the market. Moreover, the widespread adoption of chemotherapy regimens, including bendamustine, cyclophosphamide, fludarabine, etc., to alleviate disease symptoms by reducing the proliferation of cancerous cells and decreasing the production of abnormal proteins is further bolstering the market growth. Apart from this, the escalating application of plasmapheresis procedures, since they help to lower the concentration of IgM, thereby enhancing blood flow and preventing complications related to high serum viscosity, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of interferon-alpha therapy to treat the disorder owing to its several associated benefits, such as stimulating the immune system, inhibiting cell growth, and improving disease control, is expected to drive the Waldenstrom macroglobulinemia market during the forecast period. 

IMARC Group's new report provides an exhaustive analysis of the Waldenstrom macroglobulinemia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Waldenstrom macroglobulinemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Waldenstrom macroglobulinemia market in any manner.

Recent Developments:

• In July 2024, Cellectar Biosciences reported positive results from its CLOVER WaM pivotal study, which evaluated iopofosine I 131, a potential first-in-class, targeted radiotherapeutic candidate for the treatment of relapsed/refractory Waldenstrom's macroglobulinemia patients who had received at least two prior lines of therapy, including Bruton tyrosine kinase inhibitors.
• In June 2024, Mustang Bio reported that revised findings from the ongoing Phase 1/2 clinical study of MB-106, a CD20-targeted, autologous CAR T-cell treatment, reveal a promising safety and effectiveness profile in patients with Waldenstrom macroglobulinemia.
• In February 2024, Johnson & Johnson and its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced that the U.S. FDA had approved a label expansion for IMBRUVICA (ibrutinib) with an oral suspension formulation for adult patients in the treatment of Waldenström's macroglobulinemia.

Key Highlights:

• Waldenstrom macroglobulinemia affects around 1/260,000 people every year in the United States.
• Waldenstrom macroglobulinemia has a prevalence estimate of approximately 1/102,220 in Europe.
• It accounts for roughly 2% of all hematological cancers.
• The typical age at diagnosis is 72, and men are twice as likely as women to be diagnosed.
• Up to 38% of patients with Waldenstrom macroglobulinemia suffer from peripheral neuropathy.

Drugs:

Imbruvica (Ibrutinib) is a once-daily oral medicine co-developed and commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. IMBRUVICA inhibits the Bruton's tyrosine kinase (BTK) protein, which is required for normal and aberrant B cells, including certain cancer cells, to grow and spread. By inhibiting BTK, IMBRUVICA could potentially transfer abnormal B cells out of their nourishing surroundings and prevent their proliferation.

APG-2575 is a novel, orally administered Bcl-2‒selective inhibitor being developed by Ascentage Pharma. APG-2575 is intended to treat a number of hematologic malignancies by selectively inhibiting Bcl-2, restoring the normal apoptotic mechanism in malignant cells.

Acalabrutinib is a highly selective, powerful, covalent inhibitor of BTK that has shown minimal off-target activity in pre-clinical testing. This prospective new drug is being developed for the treatment of certain B-cell and other malignancies. The acalabrutinib development program involves both monotherapy and combination therapy methods in Waldenstrom macroglobulinemia.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Waldenstrom macroglobulinemia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Waldenstrom macroglobulinemia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Waldenstrom macroglobulinemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Waldenstrom macroglobulinemia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Waldenstrom macroglobulinemia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Waldenstrom macroglobulinemia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Waldenstrom macroglobulinemia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Waldenstrom macroglobulinemia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Waldenstrom macroglobulinemia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Waldenstrom macroglobulinemia across the seven major markets?
• What is the size of the Waldenstrom macroglobulinemia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Waldenstrom macroglobulinemia?
• What will be the growth rate of patients across the seven major markets?
   

Waldenstrom Macroglobulinemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Waldenstrom macroglobulinemia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Waldenstrom macroglobulinemia market?
• What are the key regulatory events related to the Waldenstrom macroglobulinemia market?
• What is the structure of clinical trial landscape by status related to the Waldenstrom macroglobulinemia market?
• What is the structure of clinical trial landscape by phase related to the Waldenstrom macroglobulinemia market?
• What is the structure of clinical trial landscape by route of administration related to the Waldenstrom macroglobulinemia market?